Latest news with #TVTX
Yahoo
2 days ago
- Business
- Yahoo
HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs
Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 10 Best Growth Stocks Under $100 to Buy Now. HC Wainwright & Co., a leading investment bank, has initiated a 'Buy' rating for Travere Therapeutics, Inc. (NASDAQ:TVTX), with a price target of $30, signaling an upside of around 100%. This confidence in the company underscores its position in the pharmaceutical sector. The company has just announced plans to present three new abstracts underscoring the impact of FILSPARI (sparsentan) in rare kidney disease at the International Podocyte Conference, taking place in Hamburg, Germany. The findings of FILSPARI, showcasing advanced reductions in urinary BAFF and sC5b9, along with dips in the proinflammatory and profibrotic biomarkers, signal a step forward in the treatment of IgAN. A laboratory technician working on a solution of rare diseases, housed in a cholic acid capsule. With net sales of FILSPARI increasing 182% year-over-year and the successful approval of FILSPARI in Europe and the UK, analysts have little doubt about the company's potential. Since the major revenue contribution comes from FILSPARI, the rising popularity and increasing adoption among nephrologists mean that Travere Therapeutics, Inc. (NASDAQ:TVTX) can continue to leverage a product that is quite differentiated. Travere Therapeutics, Inc. (NASDAQ:TVTX) is a biopharmaceutical company incorporated in 2008. This California-based giant recognizes, develops, and commercializes therapies for people suffering from rare kidney and metabolic diseases in the United States. While we acknowledge the potential of TVTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
24-02-2025
- Business
- Yahoo
Travere Therapeutics price target raised to $30 from $24 at TD Cowen
TD Cowen raised the firm's price target on Travere Therapeutics (TVTX) to $30 from $24 and keeps a Buy rating on the shares. The firm said Q4 Filspari results were in line with the preannouncement with impressive 40% quarter-over-quarter sales growth and a 37% quarter-over quarter increase in PSFs. Filspari growth in IgAN should continue in 2025 as there are multiple tailwinds and the FSGS sNDA submission should occur by the end of Q1 setting up a potential approval by year-end. See what stocks are receiving strong buy ratings from top-rated analysts. Filter, analyze, and streamline your search for investment opportunities with TipRanks' Stock Screener. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on TVTX: Travere Therapeutics Posts Strong 2024 Financial Results Strong Growth Potential and Strategic Advancements Drive Buy Rating for Travere Therapeutics Closing Bell Movers: Booking gains 3%, Akamai down 8% on earnings Is TVTX a Buy, Before Earnings? Travere Therapeutics price target raised to $47 from $45 at Guggenheim Sign in to access your portfolio
